GLP-1 agonists bind to GLP-1 receptors on pancreatic cells, which directly stimulates pancreatic cells to secrete insulin
[1] [4] Wegovy, a higher-dose subcutaneous semaglutide formulation, received FDA approval for chronic weight management in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia
Keep your three pillars- water, protein, and movement
However, clinical data confirms that weight loss is significantly slower with microdosing compared to standard therapeutic doses, often resulting in much less total weight loss over the same period
Tissue-specific peptide processing occurs through prohormone convertases that produce glucagon in the pancreas and GLP-1 and GLP-2 in the intestine 2
Inadvertent early pregnancy exposure has not consistently demonstrated teratogenic effects, but the data are limited